The PCE uses sex-specific Cox proportional-hazards regression. Natural logarithms of age, total cholesterol, HDL-C, and systolic BP are entered into race- and sex-specific linear combinations. The output is transformed through an exponential survival function to yield the estimated 10-year probability of a first hard ASCVD event. African American individuals have separate, higher-intercept equations reflecting higher population-level baseline risk.

The Framingham Heart Study, initiated in 1948, was the foundation of cardiovascular risk prediction for half a century. However, Framingham's cohort was nearly exclusively White and from a single New England town — limiting its generalizability to the diverse US population. By the 1990s, it was clear that African American adults suffered disproportionate rates of stroke and hypertension poorly captured by Framingham-derived equations. The ACC/AHA responded by pooling data from four major longitudinal cohorts: Framingham Original, Framingham Offspring, ARIC (Atherosclerosis Risk in Communities), CARDIA (Coronary Artery Risk Development in Young Adults), and CHS (Cardiovascular Health Study) — producing the first race-specific cardiovascular risk equations.

The 2013 ACC/AHA cholesterol guideline fundamentally restructured US cardiovascular prevention. Rather than targeting specific numerical LDL-C goals (as ATP III had done), the new framework asked: 'Does this patient's 10-year risk justify statin therapy?' This risk-based approach controversially expanded the population eligible for statins by an estimated 12.8–12.9 million Americans. Critics argued the PCE significantly overestimated risk in contemporary cohorts. Proponents countered that even moderate overestimation was acceptable given statins' safety profile and the massive unmet burden of preventable cardiovascular events.

In parallel with the guideline release, Paul Ridker and Nancy Cook published a landmark Lancet commentary demonstrating that the PCE systematically overestimated cardiovascular risk by 75–150% compared to contemporary high-quality cohorts. This triggered a years-long scientific debate about whether millions of Americans were being unnecessarily exposed to statins. The controversy led to significant research into recalibration, ultimately reinforcing a key principle: the PCE should initiate a clinician-patient conversation — not mechanically dictate treatment.

In 2023, the AHA published PREVENT (Predicting Risk of Cardiovascular Disease Events) equations — the most comprehensive overhaul of US cardiovascular risk prediction in a decade. PREVENT addressed the PCE's major limitations: it is race-free (eliminating race as a biological variable), extends the age range to 30–79, incorporates kidney function (eGFR) in the base model and uACR + HbA1c + SDI in the full model, and predicts heart failure in addition to ASCVD. Two major external validations in 2025 — UK Biobank (n=368,125) and Kaiser Permanente Southern California (n=559,241) — confirmed that PREVENT substantially improves calibration while maintaining similar discrimination to PCE. The critical unresolved question is what risk threshold should trigger statin initiation with PREVENT: a 4.5% PREVENT threshold appears to yield equivalent sensitivity and specificity to the current 7.5% PCE threshold.